Predicting mavacamten response in obstructive hypertrophic cardiomyopathy
Part of Heart & circulation clinical trials.
This trial tests whether a person's genetic makeup can predict how well they respond to the drug mavacamten for obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle is thickened and blocks blood flow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with obstructive hypertrophic cardiomyopathy (oHCM).
- Your condition must not be caused by other issues like high blood pressure or valve disease.
- You cannot have had a procedure to reduce heart muscle thickness (like septal reduction therapy) in the last 6 months.
- You must not have certain other heart conditions like amyloidosis or Fabry disease.
- You must not have a low baseline heart function (LVEF below 55%) or be pregnant or have uncontrolled heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called mavacamten can help people with a specific type of thickened heart muscle (obstructive hypertrophic cardiomyopathy, or oHCM) by improving how the heart uses energy. It aims to understand if this treatment can improve symptoms and function.
This trial tests if mavacamten can help people with hypertrophic cardiomyopathy (HCM) who have obstruction in the middle or tip of the heart (not the usual outflow tract). You may join if you have symptoms like chest pain or shortness of breath and a pressure gradient above 30 mmHg in these areas.
This study tests switching from mavacamten to aficamten, two newer medicines that help improve heart function in people with a thickened heart muscle (HCM) that blocks blood flow. The goal is to see if aficamten works as well or better.
This trial uses a special CT scan to create a 3D model of your heart's blood flow. It aims to see if this model can help doctors better predict how well treatments work for people with a thick heart muscle that blocks blood flow.
This study collects blood samples from people with obstructive hypertrophic cardiomyopathy (a type of heart muscle disease) to explore how genetics and other factors affect how well the drug mavacamten works. It may help doctors better understand who benefits most from this treatment.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
Hear when a new Hypertrophic Cardiomyopathy (HCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.